Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study.
The effectiveness of cabergoline in 50 men with psychogenic erectile dysfunction was investigated in a 4-month, randomized, placebo-controlled, double-blind study with validated psychological tests, and prolactin, follicle-stimulating hormone, luteinizing hormone and testosterone serum levels. Cabergoline treatment was well-tolerated and resulted in normalization of hormone levels in most cases. In the cabergoline-treated group, significant interactions between prolactin and testosterone serum concentrations were observed. Erectile function improved significantly. Sexual desire, orgasmic function, and the patient's and his partner's sexual satisfaction were also enhanced. Cabergoline may be an effective and safe alternative agent for men with psychogenic ED.
Nickel
M
M
Clinic for Psychosomatic, Inntalklinik, Simbach/Inn, Germany. m.nickel@inntalklinik.de
Moleda
D
D
Loew
T
T
Rother
W
W
Pedrosa Gil
F
F
D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D007172:Erectile Dysfunction / Q000097:blood / Q000188:drug therapy* / Q000523:psychology*; D004873:Ergolines / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007989:Libido; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D009948:Orgasm; D017060:Patient Satisfaction; D010919:Placebos; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood
D018491:Dopamine Agonists; D004873:Ergolines; D010919:Placebos; D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D000077465:Cabergoline